Emergent BioSolutions (EBS) Misses Q2 EPS, Revenue
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Emergent BioSolutions Reports Financial Results for Second Quarter 2022
August 1, 2022 4:07 PM EDTReports strong core products segment performance offset by impact of continuing post-COVID transition and re-baselining of CDMO services segmentResumes financial guidance; provides update to full year 2022 outlook
GAITHERSBURG, Md., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the second quarter ended June 30, 2022.
Central to Emergent's mission - to protect and enhance life - is our ability to provide quality products and services for the benefit of our patients and customers, said Robert G. Kramer, president and CEO of Emergent BioSolutions. We... More
